Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Reiter, N; El-Shabrawi, L; Leinweber, B; Berghold, A; Aberer, E.
Calcinosis cutis Part II. Treatment options.
J AM ACAD DERMATOL. 2011; 65(1): 15-22. Doi: 10.1016/j.jaad.2010.08.039
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Aberer Elisabeth
Co-Autor*innen der Med Uni Graz
Berghold Andrea
El-Shabrawi-Caelen Laila
Leinweber Bernd
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Because calcinosis cutis is a rare syndrome, there is a notable lack of controlled clinical trials on its treatment. The efficacy of calcinosis treatment has only been reported in single cases or small case series. No treatment has been generally accepted as standard therapy, although various treatments have been reported to be beneficial, including warfarin, bisphosphonates, minocycline, ceftriaxone, diltiazem, aluminium hydroxide, probenecid, intralesional corticosteroids, intravenous immunoglobulin, curettage, surgical excision, carbon dioxide laser, and extracorporeal shock wave lithotripsy.
Find related publications in this database (using NLM MeSH Indexing)
Biopsy, Needle -
Calcinosis - diagnosis
Ceftriaxone - therapeutic use
Combined Modality Therapy -
Drug Therapy, Combination -
Education, Medical, Continuing -
Evidence-Based Medicine -
Female -
Humans -
Immunoglobulins, Intravenous - therapeutic use
Immunohistochemistry -
Laser Therapy - methods
Lasers, Gas - therapeutic use
Male -
Minocycline - therapeutic use
Prognosis -
Recurrence -
Risk Assessment -
Severity of Illness Index -
Skin Diseases - diagnosis
Treatment Outcome -
Warfarin - therapeutic use

Find related publications in this database (Keywords)
calcinosis cutis
evidence-based medicine levels
review
treatment
© Med Uni Graz Impressum